Skip to main content

ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023

SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today reported that Richard Lowenthal, M.Sc., MSEL, co-founder and chief executive officer, and Eric Karas, chief commercial officer, will participate in a fireside chat during the SVB Securities Virtual Global Biopharma Conference 2023 on Thursday, February 16, 2023 at 2:20 p.m. ET.

A live webcast will be available in the investor section of the company’s website at www.ars-pharma.com. The webcast will be archived for 30 days following the presentation.

About ARS Pharmaceuticals, Inc.        
ARS is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The Company is developing neffy® (previously referred to as ARS-1), an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications and insect bites that could lead to life-threatening anaphylaxis. For more information, visit www.ars-pharma.com.

ARS Investor Contact:
Justin Chakma
ARS Pharmaceuticals
justinc@ars-pharma.com


Recent Quotes

View More
Symbol Price Change (%)
AMZN  220.17
+2.22 (1.02%)
AAPL  260.45
+2.00 (0.77%)
AMD  233.90
+3.67 (1.59%)
BAC  51.55
+0.45 (0.89%)
GOOG  255.22
+2.69 (1.07%)
META  741.20
+7.79 (1.06%)
MSFT  523.53
+2.99 (0.57%)
NVDA  182.13
+1.85 (1.03%)
ORCL  281.00
+8.34 (3.06%)
TSLA  434.62
-4.35 (-0.99%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.